Sequoia Receives FDA Fast Track Designation for UTI Vaccine

Sequoia Sciences received an FDA Fast Track designation for its vaccine for recurrent urinary tract infections caused by multidrug-resistant bacteria.

The vaccine recently completed its first clinical trial in women. Of the 67 patients enrolled, 30 had a two-year documented history of recurrent UTIs, a primary source of sepsis. The vaccine was well-tolerated and generated a strong immune response, the company said.

Sequoia cited a 2010 survey showing that 83 percent of urologists reported administering intravenous antibiotics to recurrent UTI patients that were resistant to all available oral antibiotics.